December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee (PCAC)

o During the morning session, the committee will discuss the following bulk drug substances nominated for inclusion on the list of bulk drug substances that can be used to compound drug products in accordance with section 503A of the FD&C Act: CJC-1295-related bulk drug substances (CJC-1295 (free base), CJC-1295 acetate, CJC-1295 with drug affinity complex (DAC) (free base), CJC-1295 DAC acetate, and CJC-1295 DAC trifluoroacetate)), and AOD-9604-related bulk drug substances (AOD-9604 acetate, and AOD-9604 (free base)).
o During the afternoon session, the committee will discuss additional bulk drug substances nominated for inclusion on the list of bulk drug substances that can be used to compound drug products in accordance with section 503A of the FD&C Act: Thymosin alpha-1-related bulk drug substances (Thymosin alpha-1 acetate, and Thymosin alpha-1 (free base)).